Dernière mise à jour : 02 septembre 2016
Détails
FichiersGeneric Name:
Siltuximab
État du projet:
Terminé
Domaine thérapeutique:
Multicentric Castleman's disease (MCD)
Fabricant:
Janssen Inc.
Brand Name:
Sylvant
Gamme de produits:
Examen en vue du remboursement
Numéro de projet :
PC0052-000
Indicateur de rendement:
S. O. – Mesures de rendement prédictives
Strength:
100mg/vial and 400mg/vial
Tumour Type:
Lymphoma
Indications:
Multicentric Castleman's Disease (MCD)
Funding Request:
For the treatment of patients with multicentric Castleman's disease (MCD) who are human immunodeficiency virus (HIV)-negative and human herpes virus-8 (HHV-8)-negative
Review Status:
Complete
Date NOC Issued:
Sponsor:
Janssen Inc.
Submission Date:
Submission Deemed Complete:
Priorisation demandée:
Non demandée
Stakeholder Input Deadline ‡:
Check-point meeting:
pERC Meeting:
Initial Recommendation Issued:
Feedback Deadline ‡:
Notification to Implement Issued:
Recommandation:
Remboursement sous critères cliniques ou conditions
pERC Meeting:
Final Recommendation Issued:
Fichiers
‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback. Deadlines for Input and Feedback are by the end of the pCODR business day (5P.M. Eastern Time) of the date noted.
Dernière mise à jour : 02 septembre 2016